⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18559571 | 0.73 | — | — | |
| SCHEMBL19228480 | 0.70 | GRM5 (0.41) | — | |
| Hymexazol SCHEMBL20729 | 0.67 | — | — | |
| SCHEMBL19573806 | 0.67 | — | — | |
| Hymexazol SCHEMBL8505342 | 0.65 | — | — | |
| Hymexazol SCHEMBL27388145 | 0.65 | — | — | |
| Hymexazol SCHEMBL27365502 | 0.65 | — | — | |
| Hymexazol SCHEMBL31379730 | 0.65 | — | — | |
| Hymexazol SCHEMBL27862054 | 0.65 | — | — | |
| Hymexazol SCHEMBL8756453 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10548896-B2 | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190240223-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | CELGENE CORPORATION (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190240222-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | CELGENE CORPORATION (US) | 2019-08-08 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |